This is a preview of subscription content, log in via an institution to check access.
References
Heller SL, Young Lin LL, Melsaether AN, Moy L, Gao Y. Hormonal effects on breast density, fibroglandular tissue, and background parenchymal enhancement. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018;38:983–96. https://doi.org/10.1148/rg.2018180035.
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235–9. https://doi.org/10.1073/pnas.87.18.7235.
Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS, et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 2010;123:3507–14. https://doi.org/10.1242/jcs.072900.
Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33:463–79.e10. https://doi.org/10.1016/j.ccell.2018.01.011.
Luo N, Guan Q, Zheng L, Qu X, Dai H, Cheng Z. Estrogen-mediated activation of fibroblasts and its effects on the fibroid cell proliferation. Transl Res. 2014;163:232–41. https://doi.org/10.1016/j.trsl.2013.11.008.
Funding
The study was partially funded by the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Johannes Czernin is a founder, board member, and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. Johannes Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. Johannes Czernin is the recipient of a grant from the US Department of Energy (DESC0012353), from the Prostate Cancer Foundation (2017 and 2019 Challenge Awards, 17CHAL02 19CHAL02), and from the Johnson Comprehensive Cancer Center NIHNCI Cancer Center Support Grant (P30 CA016042).
Jeremie Calais is the recipient of grants from the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty), the Philippe Foundation Inc. (NY, USA), and the ARC Foundation (France) (International Mobility Award SAE20160604150).
Jeremie Calais is a consultant for Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, Progenics Radiopharmaceuticals, Radiomedix, and Telix Pharmaceuticals, outside of the submitted work.
All other co-authors have no conflict of interest.
Ethical approval
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Written and oral informed consent was provided by the patient involved in this study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Image of the month
Rights and permissions
About this article
Cite this article
Sonni, I., Lee-Felker, S., Memarzadeh, S. et al. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging 48, 924–926 (2021). https://doi.org/10.1007/s00259-020-04947-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-020-04947-z